SCHEMBL14840641

SCHEMBL14840641

CCOC(=O)c1c(C)noc1-c1ccncc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.60
PKM P14618 3/20 0.60
KDM4E B2RXH2 3/20 0.59
POLB P06746 1/20 0.59
HPGD P15428 3/20 0.51
HSD17B10 Q99714 2/20 0.51
CDC7 O00311 8/20 0.49
DBF4 Q9UBU7 8/20 0.49
TSHR P16473 1/20 0.47
CASP1 P29466 1/20 0.44
NPSR1 Q6W5P4 2/20 0.43
MAPT P10636 2/20 0.43
NPC1 O15118 1/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MMP2 P08253 1/20 0.42
MMP13 P45452 1/20 0.42
MMP14 P50281 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4031918 0.87 ALDH1A1 (0.65) ALDH1A1PKMKDM4EPOLBHPGD
SCHEMBL8243211 0.84 ALDH1A1 (0.64) ALDH1A1PKMKDM4EPOLBHPGD
SCHEMBL31526126 0.84 ALDH1A1 (0.59) ALDH1A1PKMKDM4EPOLBHPGD
SCHEMBL31526118 0.83 POLB (0.61) ALDH1A1PKMKDM4EPOLBHPGD
SCHEMBL3825841 0.82 ALDH1A1 (0.56) ALDH1A1PKMKDM4EPOLBHPGD
SCHEMBL31526330 0.81 ALDH1A1 (0.57) ALDH1A1PKMKDM4EPOLBHPGD
SCHEMBL14840387 0.80 IP6K1 (0.47) ALDH1A1PKMKDM4EPOLBHPGD
SCHEMBL15897745 0.80 AR (0.56) ALDH1A1PKMKDM4EPOLBMAPT
SCHEMBL6166566 0.78 ALDH1A1 (0.59) ALDH1A1PKMKDM4EPOLBHPGD
SCHEMBL1776304 0.77 MAPK1 (0.57) ALDH1A1KDM4EPOLBHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11174272-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-11-16 US disclosed
US-20210206781-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES TAKEDA PHARMACEUTICALS CO (JP) 2021-07-08 US disclosed
US-10717748-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-07-21 US disclosed
US-20200157117-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES TAKEDA PHARMACEUTICALS CO (JP) 2020-05-21 US disclosed
US-10550129-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-02-04 US disclosed
US-20190233436-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES TAKEDA PHARMACEUTICALS CO (JP) 2019-08-01 US disclosed
US-10273245-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-04-30 US disclosed
US-20190071455-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES TAKEDA PHARMACEUTICALS CO (JP) 2019-03-07 US disclosed
EP-2763979-B1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES TAKEDA PHARMACEUTICALS CO (JP) 2018-12-26 EP disclosed
US-10144743-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-12-04 US disclosed
US-9193709-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-24 US disclosed
US-8871766-B2 Heterocyclic compounds TAKEDA PHARMACEUTICAL CO., LTD. (JP) 2014-10-28 US disclosed
US-8865717-B2 Heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-10-21 US disclosed
US-20140228373-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-08-14 US disclosed
EP-2763979-A1 1 - ARYLCARBONYL - 4 - OXY - PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Takeda Pharmaceutical Company Limited (JP) 2014-08-13 EP disclosed
US-20140088118-A1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-27 US disclosed
US-20140088146-A1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-27 US disclosed
US-8648079-B2 Heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-02-11 US disclosed
WO-2013054822-A1 1 - ARYLCARBONYL - 4 - OXY - PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-04-18 WO disclosed
US-20130090341-A1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200157117-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PSEN1 ALDH1A1 101/4885PKM 3299/4885KDM4E 251/4885
US-20190233436-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PSEN1 ALDH1A1 101/4885PKM 3299/4885KDM4E 251/4885
US-10273245-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases SNCA, HTT, PSEN1 ALDH1A1 101/4885PKM 3299/4885KDM4E 251/4885
US-11174272-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases SNCA, HTT, PSEN1 ALDH1A1 101/4885PKM 3299/4885KDM4E 251/4885
US-10144743-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases SNCA, HTT, PSEN1 ALDH1A1 101/4885PKM 3299/4885KDM4E 251/4885
US-20140228373-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, PSEN1, HTT ALDH1A1 59/4885PKM 3052/4885KDM4E 376/4885
US-10717748-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases SNCA, HTT, PSEN1 ALDH1A1 101/4885PKM 3299/4885KDM4E 251/4885
US-20140088118-A1 HETEROCYCLIC COMPOUNDS HTT, NQO1, BDNF ALDH1A1 300/4885PKM 3246/4885KDM4E 1584/4885
US-20130090341-A1 HETEROCYCLIC COMPOUNDS HTT, NQO1, BDNF ALDH1A1 300/4885PKM 3246/4885KDM4E 1584/4885
US-20140088146-A1 HETEROCYCLIC COMPOUNDS HTT, NQO1, BDNF ALDH1A1 300/4885PKM 3246/4885KDM4E 1584/4885
US-10550129-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases SNCA, HTT, PSEN1 ALDH1A1 101/4885PKM 3299/4885KDM4E 251/4885
US-20190071455-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PSEN1 ALDH1A1 101/4885PKM 3299/4885KDM4E 251/4885
US-20210206781-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PSEN1 ALDH1A1 101/4885PKM 3299/4885KDM4E 251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.